News

UZH article “From Lab to Life”

Fabienne Hartmann-Fritsch still feels most at home in the lab, even though she now spends more time in front of her PC than inspecting Petri dishes. In 2017, the biologist founded the spin-off CUTISS together with four other UZH scientists. Once clinical trials are complete, the spin-off plans to roll out personalized skin tissue therapy on the market – in other words, customized human skin grown in the lab. During her doctoral studies at the University Children’s Hospital Zurich, Hartmann-Fritsch started specializing in planning and executing clinical research projects involving humans and dealing with the legal framework. The transition from pure research to (communications) management was an easy one for her. “It’s immensely gratifying to now be able to apply the results of years’ worth of lab work,” she says. The innovative product that is supposed to increase the quality of life of people suffering from skin defects is called denovoSkin. In the second trial phase, the researchers will now test the safety and effectiveness of the skin replacement in various clinics. For Hartmann-Fritsch, this means extensive talks with medics, sponsors and the authorities.

Text: Alice Werner
Picture: Frank Brüderlin

©EBA

EBA 2019 Helsinki

CUTISS AG is present with a booth at the EBA 2019 in Helsinki. Further information about the congress, also for the upcoming events of the EBA can be found under “Learn more”

csem final

CSEM article on Innosuisse Grant

Swiss researchers want to develop the first-ever automated machine to bioengineer personalised skin grafts for therapy. The denovoCast project, a collaboration between life science start-up Cutiss AG and CSEM, has been awarded a grant of more than CHF 800’000 by Innosuisse.

EU final

CUTISS receives SME Instrument Grant

CUTISS AG receives SME Instrument Grant for 2.5 Million Euros to automate.

Read more about this on startupticker.ch –

Cutiss, SamanTree Medical and RqMicro have been selected for the SME Instrument. The startups will be supported in the Phase 2 of the SMI Instrument, with up to €2.5 million in funding.

venture final

CUTISS amongst Startup Team to fly to Boston – article on venturelab.ch

CUTISS AG is among the 10 Swiss Venture Leaders that will fly to Boston!

Ten new startups have been selected to become the next Venture Leaders Life Sciences 2018. Chosen from among the most promising Life Sciences startups in Switzerland, the team will embark on a fully packed one-week roadshow in Boston. Meet the team at the Startup Champions Seed Night event on May 2nd.
Following in the footsteps of fellow alumni like Insphero or Covagen, the Venture Leaders Life Sciences 2018 team members will join the 17th edition for a deep dive into Boston’s Life Sciences industry between May 27th and June 3rd. For an intense week, the newly constituted Swiss National Startup Team will have the opportunity to build a solid network through exchanges with local peers, meetings with key Medtech and Biotech industry leaders, and pitches in front of investors, all in order to boost their global expansion ambitions. The Boston region is considered to be one of the major Life Sciences hub worldwide, representing an ideal environment for the Swiss-based startups to get exposure and visibility as well showcasing Switzerland as a breeding ground for innovation in Life Sciences.

Scroll to Top

Newsletter

Would you like to contact us as a journalist?

This website uses cookies to ensure you get the best experience on our website.